Researchers have discovered a new general anaesthetic that, unlike most anaesthetics, also relieves pain at doses that do not cause sedation. The compound, named nidradine, was reported in Nature Communications on 16 November 2026 by a team led by researchers at the University of California, San Francisco and the Chan Zuckerberg Biohub. They screened 12,000 compounds using a high-throughput platform that filmed the behaviour of larval zebrafish in 96-well plates, looking for chemicals that produced the same behaviour as the intravenous anaesthetics etomidate and propofol, two drugs already used in hospitals. One isoxazole chemical family matched that profile, and medicinal chemistry optimisation of it produced nidradine. Like etomidate and propofol, nidradine acts on GABAA receptors, the brain’s main inhibitory signalling system, and it proved effective in both zebrafish and mice.
What the Evidence Shows
Most general anaesthetics put patients to sleep without blocking pain, so pain relief during surgery usually comes from separate drugs, often opioids with their own risks. A single agent that does both could simplify anaesthesia and reduce that reliance, which is why the team screened for behaviour rather than for a single molecular target. The zebrafish platform let them test thousands of compounds quickly by watching how the tiny fish moved, rested and responded, before checking the most promising candidates in mice. The work is still at the laboratory stage: nidradine has not been tested in people, and its safety, dosing and side effects in humans are unknown. The University of California, San Francisco and the Chan Zuckerberg Biohub have applied for a patent on nidradine and related compounds. Even so, the discovery shows how behavioural screening in a small fish can find drug candidates that a purely chemical search might miss. Reporting and analysis from sources such as Nature track the same developments, and specialists following the new anaesthetic nidradine say the direction is now consistent across independent lines of evidence.
The Wider Context
The wider context is a research landscape in which replication and open data now decide reputations. Findings connected to the new anaesthetic nidradine are being checked by independent groups with shared datasets, and the teams involved publish their methods in full so rivals can test every step. That discipline is slower than a headline cycle, but it is why results in this area increasingly survive first contact with scrutiny.
What Happens Next
What happens next in the story of the new anaesthetic nidradine will be decided by follow-up work already under way: larger samples, longer observation and instruments that have not yet come online. The researchers involved are unusually united on one point, that the current results justify the next investment of time and money. Readers will not have to wait long for the first tests of that claim. You can follow related developments in our coverage of science.
None of this will be settled by a single announcement, study or product launch. The pattern to watch is accumulation: independent confirmations, honest reporting of failures and steady improvement in the underlying numbers. Readers who follow those signals, rather than the loudest claim of the week, will understand this subject better than most of the commentary surrounding it suggests is possible.